Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Summit Therapeutics PLC (SMMT) had Normalized Pre-Tax Income of $-215.70M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-215.70M |
|
-- |
|
-- |
|
$220.50M |
|
$-220.50M |
|
$4.80M |
|
$-215.70M |
|
|
Normalized Pre-Tax Income |
$-215.70M |
$-215.70M |
|
$-215.70M |
|
$-215.70M |
|
$-215.70M |
|
$-220.50M |
|
$-220.45M |
|
778.18M |
|
778.18M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$720.58M |
|
$1.78M |
|
$31.61M |
|
$752.18M |
|
$103.57M |
|
-- |
|
$18.64M |
|
$122.20M |
|
$629.98M |
|
$628.01M |
|
$629.98M |
|
793.12M |
|
| Cash Flow Statement Financials | |
$-263.42M |
|
$222.66M |
|
$234.88M |
|
$225.58M |
|
$419.68M |
|
$194.10M |
|
$141.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-264.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.24% |
|
-34.35% |
|
-28.68% |
|
-34.24% |
|
$0.79 |
|
$-0.34 |
|
$-0.34 |
|